Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05173714 · ClinicalTrials.gov registry record · Phase 2
Sit Less, Interact and Move More (SLIMM) 2 Study
A Phase 2 study of Obesity and Chronic Kidney Diseases, sponsored by Srinvasan Beddhu.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 156
- Enrollment target
- 2
- Study locations
NCT05173714: Recruiting Phase 2 study of Obesity and Chronic Kidney Diseases, sponsored by Srinvasan Beddhu.
NCT05173714 is a Phase 2 study of Obesity and Chronic Kidney Diseases that is actively recruiting participants, run by Srinvasan Beddhu. The registered enrollment target is 156 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (81% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05173714, a Phase 2 study of Obesity and Chronic Kidney Diseases, is actively recruiting participants, sponsored by Srinvasan Beddhu.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 156 participants
- Enrollment target
- 2
- Study locations
Study Summary
* Prolonged sitting (sedentary behavior) is a risk factor for decreased kidney function, obesity, diabetes and mortality. Prolonged sitting is associated with decreased kidney function and increased risk of diabetes, heart disease and death. * In a previous pilot study funded by NIH, it was shown that a Sit Less, Interact and Move More (SLIMM) intervention targeting sedentary behavior in people with kidney disease was able to decrease prolonged sitting but that effect was not sustained. * Therefore, the researchers are currently conducting a follow-up study named Sit Less, Interact and Move More (SLIMM) 2. * This NIH funded study is conducted at the University of Utah and Stanford University. * The purpose of this study is to see if guided resistance training (to improve muscle strength) and semaglutide (FDA approved diabetes and weight loss medication that might also improve physical function) can boost adherence to the SLIMM Intervention and reduce sedentary behavior.
Primary Outcome
The primary analysis will provide estimates and confidence intervals for the three arms comparisons of changes in sedentary duration from randomization (at 3 months) to the average of changes at months 8, 10 and 12 between the randomized groups that constitute the co-primary comparisons under the study design
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Semaglutide
- BEHAVIORAL SLIMM
- BEHAVIORAL Standard Resistance Training
- BEHAVIORAL Guided Resistance Training
Study Locations (2)
California
- Stanford University - Stanford
Utah
- University of Utah - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 156 participants |
| Start Date | 2021-12-01 |
| Est. Completion | 2027-03-31 |
| Phase | Phase 2 |
What NCT05173714 shows while recruiting
NCT05173714 is an interventional study that assigns participants to a tested intervention. The registered 156 participants enrollment target is mid-sized for trials with a published cap, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (81% lower).
The record links to 2 conditions, with Obesity appearing as the primary indexed condition, and to 5 interventions - of which Placebo is the first listed.
NCT05173714 reports a single indexed study location in California, Utah.
Frequently Asked Questions
What is clinical trial NCT05173714 about?
NCT05173714 is a clinical study titled "Sit Less, Interact and Move More (SLIMM) 2 Study". * Prolonged sitting (sedentary behavior) is a risk factor for decreased kidney function, obesity, diabetes and mortality. Prolonged sitting is associated with decreased kidney function and increased risk of diabetes, heart disease and death. * In a previous pilot study funded by NIH, it was shown th...
What is the current status of trial NCT05173714?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 156 participants. The study started on 2021-12-01. Estimated completion is 2027-03-31.
What conditions does trial NCT05173714 study?
This clinical trial studies the following conditions: Obesity, Chronic Kidney Diseases.
What interventions are being tested in trial NCT05173714?
The interventions under investigation include: Placebo (DRUG), Semaglutide (DRUG), SLIMM (BEHAVIORAL), Standard Resistance Training (BEHAVIORAL), Guided Resistance Training (BEHAVIORAL).
Who is sponsoring clinical trial NCT05173714?
This trial is sponsored by Srinvasan Beddhu, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05173714 being conducted?
This trial has 2 study locations across California, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05173714's enrollment target sits among peer trials
156 366th of 1053 higher than 687 of 1,053 other Obesity trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Obesity trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
TIRzepatide for the Treatment of Obesity in Patients With Atrial Fibrillation
RECRUITING · Phase 2
-
Tirzepatide: Reversal of Lipotoxicity and Adipose Tissue Dysfunction in Humans With Overweight/Obesity
RECRUITING · Phase 2
-
Convergent Mechanisms Underlying Reprometabolic Syndrome in Women
RECRUITING · Phase 2
-
Arterial Destiffening Effects of SGLT2 Inhibition in Veterans With Obesity
RECRUITING · Phase 2
-
A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
RECRUITING · Phase 2
-
Pharmacological and Behavioral Treatment After Bariatric Surgery
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03082755 · 156 participants · Phase 4
Nighttime Agitation and Restless Legs Syndrome in People With Alzheimer's Disease
- NCT04047628 · 156 participants · Phase 3
Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)
- NCT04166877 · 156 participants · Phase 4
Magnesium Infusion for Pain Management in Critically Ill Trauma Patients
- NCT04533464 · 156 participants · Phase 2
MultiStem® for Treatment of Trauma Induced Multiple Organ Failure/Systemic Inflammatory Response Syndrome
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI